Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers
Huseman E, Lo A, Fedorova O, Elia J, Gueble S, Lin K, Sundaram R, Oh J, Liu J, Menges F, Rees M, Ronan M, Roth J, Batista V, Crawford J, Pyle A, Bindra R, Herzon S. Mechanism of Action of KL-50, a Candidate Imidazotetrazine for the Treatment of Drug-Resistant Brain Cancers. Journal Of The American Chemical Society 2024, 146: 18241-18252. PMID: 38815248, PMCID: PMC11409917, DOI: 10.1021/jacs.3c06483.Peer-Reviewed Original ResearchDNA repair capacityDifferential DNA repair capacityDNA interstrand cross-linksRepair capacityInterstrand cross-linksDisplacement of fluorideDNA repairCross-linkingAberrant DNA repairLesionsHealthy tissueBrain cancerRing openingHealthy cellsMGMTSelective chemotherapyGenotoxic agentsTumorChemical DNA modificationsCancerMultistep processRepairDNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology
Rahman R, Shi D, Reitman Z, Hamerlik P, de Groot J, Haas-Kogan D, D’Andrea A, Sulman E, Tanner K, Agar N, Sarkaria J, Tinkle C, Bindra R, Mehta M, Wen P. DNA damage response in brain tumors: A Society for Neuro-Oncology consensus review on mechanisms and translational efforts in neuro-oncology. Neuro-Oncology 2024, 26: 1367-1387. PMID: 38770568, PMCID: PMC11300028, DOI: 10.1093/neuonc/noae072.Peer-Reviewed Original ResearchConsensus reviewDNA damage responseIDH wild-type glioblastomaIDH-mutant gliomasClinical trial design considerationsMechanisms of resistanceTrial design considerationsCombination therapyDevelopment of DDR inhibitorsDNA damage response pathwayPreclinical modelsDamage responseDDR inhibitorsNeuro-oncologyBrain tumorsBiomarker developmentTherapyResponse to DNA damageDNA damageTranslational effortsTumor